<DOC>
	<DOC>NCT02979912</DOC>
	<brief_summary>Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous platelet lysate.</brief_summary>
	<brief_title>Autologous Platelet Lysate in Corneal Epithelial Defects</brief_title>
	<detailed_description>Autologous platelet lysate (PL) will be given to patients diagnosed with persistent corneal epithelial ulcers (PED) who are unresponsive to conventional therapy to promote the healing of PED. PL will be dispensed into sterile eye droppers, and these eye droppers will be stored ideally at âˆ’20C and thaw once for use, then will be kept in the refrigerator at +4C, to be taken in multiple doses.</detailed_description>
	<criteria>1. Cognitive ability to understand and sign the consent form. 2. Corneal ulcers that did not reepithelialise after 1 week of conventional treatment (therapeutic contact lenses, topical artificial tears, eye packs and antibiotic eyedrops). 3. Clinical indications: corneal ulcer due to caustic substances, corneal epitheliopathy, corneal lesions following cataract surgery, recurrent ulcerative keratitis, corneal lesions due to a foreign body. 4. Good compliance with the study regimen and availability for the duration of the entire study period. 1. Corneal ulcers which developed tissue scars. 2. Pregnant or lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Persistent corneal epithelial defect</keyword>
	<keyword>Platelet Lysate</keyword>
</DOC>